<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00269685</url>
  </required_header>
  <id_info>
    <org_study_id>00-33-R2</org_study_id>
    <nct_id>NCT00269685</nct_id>
  </id_info>
  <brief_title>Comparison of Vasopressin and Other Pressors in Septic Shock</brief_title>
  <official_title>Comparative Prospective Study of Vasopressin and Catecholamine in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the classical tactics in the treatment of septic
      shock (dopamine, noradrenalin and dobutamine) to the use of vasopressin as first choice
      pressor.

      Vasopressin seems to be an interesting alternative in the treatment of septic shock. To this
      date, available studies have showed that it could correct hyperkinetic syndrome and
      vasoplegia in septic shocks without noticeable side effect. It as been demonstrated that
      vasopressin improves renal function, as no effect on digestive organs and as no metabolic
      effect.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficiency of vasopressine to the standard and usual treatment of septic shock on the reverse of the hemodynamic criterion of septic shock</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare these two categories of treatment on:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tonometric parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in term of tolerance: metabolic effects (increase in lactate and glycaemia), cardiac effects (tachycardia being defined as a heart rate increase of 15%), increase of cardiac enzymes (troponine, CK, CK-MB), and cutanuous vasoconstriction.</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Shock, Septic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vasopressin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Legally major patient presenting a septic shock.

        The time window between beginning of symptoms and onset of treatment is established at 12
        hours.

        The patient must be intubated and mechanically ventilated.

        Patient presenting a mean arterial blood pressure of less than 60 mm Hg after adequate
        fluid resuscitation (at least 1 L of colloid or crystalloid) and 10 ug/Kg/min of dopamine.

        Patient presenting a cardiac index of at least 3 L/min/m2

        Exclusion Criteria:

          -  Shock other than septic

          -  cardiac hypokinesia

          -  a pre-existing organic renal failure that needs hemodyalisis

          -  oesophagal or gastric phatology that would lead to a naso-gastric tube
             contraindication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Lesur, Ph d</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <reference>
    <citation>American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992 Jun;20(6):864-74. Review.</citation>
    <PMID>1597042</PMID>
  </reference>
  <reference>
    <citation>Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997 Mar 4;95(5):1122-5.</citation>
    <PMID>9054839</PMID>
  </reference>
  <reference>
    <citation>Luk J, Ajaelo I, Wong V, Wong J, Chang D, Chou L, Reid IA. Role of V1 receptors in the action of vasopressin on the baroreflex control of heart rate. Am J Physiol. 1993 Sep;265(3 Pt 2):R524-9.</citation>
    <PMID>8214142</PMID>
  </reference>
  <reference>
    <citation>Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999 Oct;47(4):699-703; discussion 703-5.</citation>
    <PMID>10528604</PMID>
  </reference>
  <reference>
    <citation>Reid IA. Role of vasopressin deficiency in the vasodilation of septic shock. Circulation. 1997 Mar 4;95(5):1108-10. Review.</citation>
    <PMID>9054835</PMID>
  </reference>
  <reference>
    <citation>Rozenfeld V, Cheng JW. The role of vasopressin in the treatment of vasodilation in shock states. Ann Pharmacother. 2000 Feb;34(2):250-4. Review.</citation>
    <PMID>10676834</PMID>
  </reference>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2005</study_first_submitted>
  <study_first_submitted_qc>December 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2005</study_first_posted>
  <last_update_submitted>May 26, 2006</last_update_submitted>
  <last_update_submitted_qc>May 26, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2006</last_update_posted>
  <keyword>Septic shock</keyword>
  <keyword>catecholamine</keyword>
  <keyword>vasopressin</keyword>
  <keyword>tonometria</keyword>
  <keyword>lactate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

